CNTB vs. URGN, ATAI, LFCR, HRTX, DSGN, ELDN, CMPS, FULC, SOPH, and LRMR
Should you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include UroGen Pharma (URGN), Atai Life Sciences (ATAI), Lifecore Biomedical (LFCR), Heron Therapeutics (HRTX), Design Therapeutics (DSGN), Eledon Pharmaceuticals (ELDN), COMPASS Pathways (CMPS), Fulcrum Therapeutics (FULC), SOPHiA GENETICS (SOPH), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry.
Connect Biopharma vs.
Connect Biopharma (NASDAQ:CNTB) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations, community ranking and media sentiment.
In the previous week, UroGen Pharma had 2 more articles in the media than Connect Biopharma. MarketBeat recorded 4 mentions for UroGen Pharma and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.00 beat UroGen Pharma's score of 0.74 indicating that Connect Biopharma is being referred to more favorably in the media.
UroGen Pharma received 348 more outperform votes than Connect Biopharma when rated by MarketBeat users. Likewise, 73.94% of users gave UroGen Pharma an outperform vote while only 72.00% of users gave Connect Biopharma an outperform vote.
Connect Biopharma currently has a consensus target price of $8.00, suggesting a potential upside of 672.20%. UroGen Pharma has a consensus target price of $43.70, suggesting a potential upside of 325.51%. Given Connect Biopharma's higher possible upside, equities research analysts clearly believe Connect Biopharma is more favorable than UroGen Pharma.
Connect Biopharma has a net margin of 0.00% compared to UroGen Pharma's net margin of -129.11%.
Connect Biopharma has a beta of -0.44, meaning that its stock price is 144% less volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.
Connect Biopharma has higher earnings, but lower revenue than UroGen Pharma.
58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by company insiders. Comparatively, 5.1% of UroGen Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
UroGen Pharma beats Connect Biopharma on 9 of the 15 factors compared between the two stocks.
Get Connect Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Connect Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:CNTB) was last updated on 1/21/2025 by MarketBeat.com Staff
Free CNTB Stock Alerts